美股异动丨Agios Pharmaceuticals盘前涨近12%，获美国FDA批准扩大血液病药物的使用范围

Core Viewpoint - Agios Pharmaceuticals' stock rose nearly 12% to $27.5 following FDA approval to expand the use of its blood disorder drug, mitapivat, for treating anemia in adult patients with α- or β-thalassemia [1] Company Summary - Agios Pharmaceuticals is a U.S.-based pharmaceutical company focused on developing treatments for blood disorders [1] - The drug mitapivat, marketed under the brand name Aqvesme, is currently undergoing testing for its efficacy in treating anemia associated with α- or β-thalassemia [1]